Cheng-lin Li

209 Tongshan Road
Xuzhou, 221004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

6H2L, a novel derivative of bifendate, dually suppresses glycolysis and glutaminolysis in hepatocellular carcinoma via inhibiting YAP stability.

6H2L, a novel derivative of bifendate, dually suppresses glycolysis and glutaminolysis in hepatocellular carcinoma via inhibiting YAP stability.

Journal: Chemico-biological interactions

Published: December 22, 2025

Dual inhibition of glycolysis and glutaminolysis by targeting FOXO3 for hepatocellular carcinoma treatment.

Dual inhibition of glycolysis and glutaminolysis by targeting FOXO3 for hepatocellular carcinoma treatment.

Journal: Oncogene

Published: September 10, 2025

Shikonin alleviates renal tubulointerstitial fibrosis in diabetic nephropathy via CCR5/ TGF-β1 signaling axis mediating EMT.

Shikonin alleviates renal tubulointerstitial fibrosis in diabetic nephropathy via CCR5/ TGF-β1 signaling axis mediating EMT.

Journal: European journal of pharmacology

Published: July 01, 2025

A facile liquid biopsy assay for highly efficient CTCs capture and reagent-less monitoring of immune checkpoint PD-L1 expression on CTCs with non-small cell lung cancer patients.

A facile liquid biopsy assay for highly efficient CTCs capture and reagent-less monitoring of immune checkpoint PD-L1 expression on CTCs with non-small cell lung cancer patients.

Journal: Biosensors & bioelectronics

Published: December 10, 2024

Correction: A multifunctional black phosphorus nanosheet-based immunomagnetic bio-interface for heterogeneous circulating tumor cell capture and simultaneous self-identification in gastric cancer patients.

Correction: A multifunctional black phosphorus nanosheet-based immunomagnetic bio-interface for heterogeneous circulating tumor cell capture and simultaneous self-identification in gastric cancer patients.

Journal: Nanoscale

Published: November 21, 2024

Apolipoprotein B100 acts as a tumor suppressor in ovarian cancer via lipid/ER stress axis-induced blockade of autophagy.

Apolipoprotein B100 acts as a tumor suppressor in ovarian cancer via lipid/ER stress axis-induced blockade of autophagy.

Journal: Acta pharmacologica Sinica

Published: June 17, 2024

Layer-by-layer fabrication of alginate/polyethyleneimine multilayer on magnetic interface with enhanced efficiency in immuno-capturing circulating tumor cells.

Layer-by-layer fabrication of alginate/polyethyleneimine multilayer on magnetic interface with enhanced efficiency in immuno-capturing circulating tumor cells.

Journal: Analytica chimica acta

Published: February 02, 2024

Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma

Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: May 15, 2023

A multifunctional black phosphorus nanosheet-based immunomagnetic bio-interface for heterogeneous circulating tumor cell capture and simultaneous self-identification in gastric cancer patients.

A multifunctional black phosphorus nanosheet-based immunomagnetic bio-interface for heterogeneous circulating tumor cell capture and simultaneous self-identification in gastric cancer patients.

Journal: Nanoscale

Published: February 01, 2023

PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus.

PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus.

Journal: BMC medical genomics

Published: July 14, 2021

Sarsasapogenin restores podocyte autophagy in diabetic nephropathy by targeting GSK3β signaling pathway.

Sarsasapogenin restores podocyte autophagy in diabetic nephropathy by targeting GSK3β signaling pathway.

Journal: Biochemical pharmacology

Published: April 20, 2021

Targeting the ILK/YAP axis by LFG-500 blocks epithelial-mesenchymal transition and metastasis.

Targeting the ILK/YAP axis by LFG-500 blocks epithelial-mesenchymal transition and metastasis.

Journal: Acta pharmacologica Sinica

Published: December 22, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026